CareFirst Appealed Ruling in Johnson & Johnson Case
CareFirst challenged a summary judgment favoring Johnson & Johnson in an antitrust patent acquisition dispute.
Updated on Sept. 22, 2026 in Healthcare
Live Poll
Should federal antitrust law require proof of specific intent to exclude rivals to establish illegal monopolization?
CareFirst filed an appeal following the U.S. District Court for the Eastern District of Virginia's February 10, 2026, decision to grant summary judgment to Johnson & Johnson. The dispute centers on whether Johnson & Johnson’s acquisition of four Momenta Pharmaceuticals patents violated the Sherman Act.
Why it matters
This case tests the legal standard for monopolization, specifically whether Section 2 of the Sherman Act requires proof of specific intent to exclude competitors. The outcome could significantly influence how courts analyze patent acquisitions in the pharmaceutical industry.
The legal dispute involves the acquisition of 4 manufacturing patents originally held by Momenta Pharmaceuticals. The litigation remains ongoing while the parties await the next phase of the appellate process.
The players
CareFirst
This is a health insurance organization currently involved in antitrust litigation regarding patent acquisitions.
Johnson & Johnson
This is a multinational pharmaceutical and medical technology corporation that acquired Momenta Pharmaceuticals manufacturing patents.
Momenta Pharmaceuticals
This is a former biotechnology company whose manufacturing patents are the subject of the current antitrust lawsuit.
Federal Trade Commission
This is an independent federal agency that protects consumers and promotes competition through the enforcement of antitrust laws.
The details
CareFirst alleges that Johnson & Johnson violated Section 2 of the Sherman Act through the acquisition of the manufacturing patents, while Johnson & Johnson maintains it was unaware of the patent contents at the time of the deal. The Federal Trade Commission has joined the conversation by filing an amicus brief, arguing that proving specific intent should not be a prerequisite for finding monopolization.
Timeline
December 2025: Portions of antitrust claims survived summary judgment.
January 14, 2026: The court granted summary judgment to Johnson & Johnson.
February 10, 2026: The court directed entry of final judgment for Johnson & Johnson.
October 8, 2026: CareFirst's reply brief is due.
Market Landscape
This litigation follows the historical application of Section 2 of the Sherman Act regarding corporate monopolization. It represents a potential shift in how courts interpret the requirement of intent when evaluating large-scale patent acquisitions by dominant firms.
The resolution of this case could determine the future pricing and availability of generic drug alternatives for consumers. Changes in how patent acquisitions are regulated directly affect how much competition exists in the pharmaceutical market.
The takeaway
The case highlights the complex intersection between intellectual property rights and antitrust enforcement in the pharmaceutical sector. Legal standards regarding intent remain a critical factor for businesses navigating high-stakes patent acquisitions.
What happens next
CareFirst is scheduled to submit its reply brief to the appellate court on October 8, 2026.
Further reading
For more context on how these legal shifts impact the industry, visit the Healthcare section.
Live Poll
Should federal antitrust law require proof of specific intent to exclude rivals to establish illegal monopolization?
